News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Johnson & Johnson to Pay Over $81 Million in Topamax Drug Case
April 29, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WASHINGTON (Reuters) - Two Johnson and Johnson subsidiaries agreed to pay more than $81 million to resolve allegations of illegal promotion of the epilepsy drug Topamax, the U.S. Justice Department said on Thursday.
Twitter
LinkedIn
Facebook
Email
Print
Legal
Johnson & Johnson Family of Companies
MORE ON THIS TOPIC
Vaccines
Former CDC, FDA Chiefs Decry Vaccine Policy Changes as ACIP Meeting Begins
December 4, 2025
·
2 min read
·
Dan Samorodnitsky
FDA
New Approach Methodologies: Redefining Animal Testing Alternatives
December 4, 2025
·
1 min read
·
BioSpace Insights
Policy
New UK/EU Rules and AI Adoption Define CRO Priorities for 2026
December 3, 2025
·
4 min read
·
Jennifer Smith-Parker
Vaccines
ACIP To Discuss Hep B, Childhood Vaccine Schedule Under New Chair Who Linked COVID Shots to Cancer
December 2, 2025
·
2 min read
·
Tristan Manalac